Heterocyclic compound
US10610520B2 · kind B2 · utility
8Cited by
30References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 30, 2017 |
| Grant date | Apr 7, 2020 |
| Priority date | — |
| Expiry date | Mar 30, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N9/18
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates to a compound represented by the formula (I):
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.